# A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer

> **NCT01773889** · PHASE2 · TERMINATED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 2 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Extraovarian Peritoneal Cancer
- Fallopian Tube Carcinoma

## Interventions

- **DRUG:** Denileukin Diftitox/SC Pegylated IFNα-2a

## Key facts

- **NCT ID:** NCT01773889
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773889, "A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01773889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*